Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1039/d0cs01118e http://scihub22266oqcxt.onion/10.1039/d0cs01118e 33524090!ä!33524090 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Chem+Soc+Rev 2021 ; 50 (6): 3647-3655 Nephropedia Template TP {{tp|p=33524090|t=2021. Antiviral drug discovery: preparing for the next pandemic |pdf=|usr=}}{{33524090}} gab.com Text Antiviral drug discovery: preparing for the next pandemic JO: Chem Soc Rev http://www.kidney.de/pget.php?&tw=1&pmid=33524090 #FOAvip Clinically approved antiviral drugs are currently available for only 10 of the more than 220 viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need for compounds that can be rapidly mobilised for the treatment of re-emerging or emerging viral diseases, while vaccine development is underway. We review the current status of antiviral therapies focusing on RNA viruses, highlighting strategies for antiviral drug discovery and discuss the challenges, solutions and options to accelerate drug discovery efforts. Twit Text FOAVip Antiviral drug discovery: preparing for the next pandemic ????Chem Soc Rev http://www.kidney.de/pget.php?&tw=1&pmid=33524090 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33524090 #FOAvip English Wikipedia <ref>{{Cite pmid|33524090}}</ref> Antiviral drug discovery: preparing for the next pandemic #MMPMID33524090 Adamson CS; Chibale K; Goss RJM; Jaspars M; Newman DJ; Dorrington RA Chem Soc Rev 2021[Mar]; 50 (6): 3647-3655 PMID33524090show ga Clinically approved antiviral drugs are currently available for only 10 of the more than 220 viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need for compounds that can be rapidly mobilised for the treatment of re-emerging or emerging viral diseases, while vaccine development is underway. We review the current status of antiviral therapies focusing on RNA viruses, highlighting strategies for antiviral drug discovery and discuss the challenges, solutions and options to accelerate drug discovery efforts. |*COVID-19 Drug Treatment[MESH] |Antiviral Agents/chemistry/*pharmacology[MESH] |Biological Products/chemistry/pharmacology[MESH] |COVID-19/prevention & control/virology[MESH] |Coronavirus Protease Inhibitors/chemistry/pharmacology[MESH] |Drug Discovery/*methods[MESH] |Humans[MESH] |Molecular Docking Simulation[MESH] |Molecular Targeted Therapy/*methods[MESH] |Nucleic Acid Synthesis Inhibitors/chemistry/pharmacology[MESH] |Pandemics/*prevention & control[MESH] |RNA, Viral/*antagonists & inhibitors/chemistry/genetics/metabolism[MESH] |SARS-CoV-2/chemistry/drug effects/enzymology/genetics[MESH]Antiviral drug discovery: preparing for the next pandemic (epmc).pdf DeepDyve Pubget Overpricing